PM
RVNC

Parametrica Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Parametrica Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,092
Closed -$203K – 205
2020
Q3 		$203K Buy
+8,092
New +$212K 0.38% 83

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Parametrica Management's RVNC Position: Q4 2020 in Review

Parametrica Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2020, closing a stake of 8,092 shares — an estimated $203K sold.

Parametrica Management first reported a position in RVNC in Q3 2020 and held it in 1 quarter. The position peaked at $203K in Q3 2020. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2020.

  • Parametrica Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Parametrica Management sold 8,092 Revance Therapeutics, Inc. shares in Q4 2020, an estimated $203K.
  • Parametrica Management first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Parametrica Management's Revance Therapeutics, Inc. position peaked at $203K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2020.

Based on Parametrica Management's 13F filing for Q4 2020, filed 16 Feb 2021.